

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

CENTRE FOR HEALTH TECHNOLOGY EVALUATION

Technology Appraisals

**Consultation on Batch 50 draft remits and draft scopes and
summary of comments and discussions at scoping workshops**

Topic ID	Topic title
994	Sarilumab for previously treated moderate to severe active rheumatoid arthritis
851	Autologous chondrocyte implantation with Chondrosphere for treating articular cartilage defects in the knee

Provisional Title	Sarilumab for previously treated moderate to severe active rheumatoid arthritis		
Topic Selection ID Number	6683	Wave / Round	R68
TA ID Number	ID994		
Company	Sanofi		
Anticipated licensing information	*** Commercial in confidence text removed***		
Draft remit	To appraise the clinical and cost effectiveness of sarilumab within its marketing authorisation for previously treated active moderate or severe rheumatoid arthritis		
Main points from consultation	<p>Following the consultation exercise and the scoping workshop, the Institute is of the opinion that an appraisal of sarilumab for previously treated moderate to severe active rheumatoid arthritis is <u>appropriate</u>.</p> <p>The proposed remit is <u>not</u> appropriate. Consultees and Commentators considered the wording of the remit to be appropriate; however the technical team noted that the word order in the proposed remit was not consistent with the wording of the remits for previous appraisals of rheumatoid arthritis.</p> <p>At the DP3 meeting, it was suggested that sarilumab would be an appropriate topic to go through the ATA process. The company considered this process appropriate for sarilumab in comparison with tocilizumab and/or adalimumab. However the company commented that this approach would not address the unmet need for therapies for people with moderate active disease who have failed on conventional DMARDs. *** Commercial in confidence text removed***</p> <p>There were no substantive changes to the scope following consultation.</p>		
Population size	<p>Between 10,400 and 34,600 people would be eligible for treatment with sarilumab.</p> <p>The prevalence of rheumatoid arthritis in the UK estimated to be 0.44% in males and 1.16% in females; when applied to the England population, this is approximately 530,500 people.</p> <p>*** Commercial in confidence text removed***</p>		
Process (TA/HST)	TA		
Proposed changes to remit (in bold)	To appraise the clinical and cost effectiveness of sarilumab within its marketing authorisation for previously treated active moderate or to severe active rheumatoid arthritis		
Costing implications of remit change	The cost Sarilumab is not yet known. It would offer an additional treatment option and the cost of selected comparator treatments range from £9,200 to £13,600 per person per year. The cost impact cannot be estimated at this stage. Should treatment prove more effective, there may be decreased use of existing services.		

Timeliness statement	Assuming that the anticipated date of the marketing authorisation is the latest date that we are aware of and the expected referral date of this topic, issuing timely guidance for this technology will be possible.
-----------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Provisional Title	Autologous chondrocyte implantation with Chondrosphere for treating articular cartilage defects		
Topic Selection ID Number	7651	Wave/round	R130
TA ID Number	ID851		
Company	Co.Don		
Anticipated licensing information	*** Commercial in confidence text removed***		
Draft remit	To appraise the clinical and cost effectiveness of Chondrosphere within its marketing authorisation for treating articular cartilage defects.		
Main points from consultation	<p>Following the consultation exercise and the scoping workshop, the Institute is of the opinion that an appraisal of chondrosphere for treating articular cartilage defects is <u>appropriate</u>.</p> <p>The proposed remit is appropriate. No changes are required.</p> <p>The company clarified that the marketing authorisation could additionally include *** Commercial in confidence text removed***The title and population in the scope have therefore been updated so that they are not limited to defects of the knee.</p>		
Population size	Approximately 10,000 people with cartilage defects requiring treatment but the number eligible for treatment such as Chondrosphere is likely to be much less. The eligible population is estimated by NIHR HSC to be 200 - 500 patients per year.		
Process (TA/HST)	TA		
Proposed changes to remit (in bold)	None		
Costing implications of remit change	Chondrosphere would provide an additional treatment option for this patient group. The cost and impact on existing services is not yet known.		
Timeliness statement	Assuming that the anticipated date of the marketing authorisation is the latest date that we are aware of and the expected referral date of this topic, issuing timely guidance for this technology will be possible.		